Issued: Monday 29 April 2013, London UK GlaxoSmithKline (GSK) plc and Impax Pharmaceuticals today announced that they are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan. IPX066 is a …
Issued: Friday 26 April 2013, London UK GlaxoSmithKline plc (LSE:GSK) today announced the submission of a regulatory application in the European Union for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with chronic …
Wednesday 24 April 2013, London UK GSK delivers Q1 2013 core EPS of 26.9p and dividend of 18p Core EPS of 26.9p and dividend of 18p Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year …
Issued: Monday 22 April 2013, London UK and South San Francisco, CA, USA GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) …
Issued: Friday 19 April 2013, London UK GSK supports fair competition and we very strongly believe that we acted within the law, as the holder of valid patents for paroxetine, in entering the agreements under investigation. These arrangements resulted in …
Issued: 17th April 2013, London UK and South San Francisco, CA, USA GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) …
Issued: Wednesday 3 April 2013, London UK GlaxoSmithKline plc (GSK) today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis – a condition that …
Issued: Wednesday 3 April 2013, London UK GlaxoSmithKline plc announced today the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK. Following a decentralised procedure, Germany’s Paul Ehrlich Institut (PEI) …
Issued: 25 March, 2013, London UK GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) in response to the Biologics License Application (BLA) for its Pandemic Influenza …
-Report sets out 23 forward-looking commitments to help measure future performance Issued: Wednesday 20 March 2013, London UK GSK has today published its corporate responsibility report, in which it reiterates its commitment to operate responsibly, openly …
March 18, 2013 – Philadelphia The Children’s Hospital of Philadelphia is proud to announce a $500,000 gift from the GlaxoSmithKline (GSK) Foundation. The donation will greatly enhance the GlaxoSmithKline Hope for Families Fund, an endowment fund which was …
Issued: Wednesday 13 March 2013, London UK GSK and the McLaren Group announce new science education initiative to inspire young people into science and engineering careers GSK has today announced a new programme for its ‘Scientists in Sport’ education …
Issued: Thursday 7 March 2013, London UK – LSE Announcement GlaxoSmithKline plc (GSK) today announced the submission of a Marketing Authorisation Application (MAA) for albiglutide, with the proprietary name EPERZAN™, to the European Medicines Agency (EMA). …
Atlanta, Georgia, 6 March, 2013- ViiV Healthcare today announced 24-week data from the Phase III SAILING (ING111762) study evaluating the investigational integrase inhibitor dolutegravir in patients with HIV-1 who are failing on current therapy, but had …
- Agreement brings the number of voluntary licences granted by ViiV Healthcare to 14 London, UK - 27 February, 2013 ViiV Healthcare today announced a collaboration with the Medicines Patent Pool (MPP), the UN-backed public health mechanism created in July …
30 January 2013 Responding to a news article in The Guardian this morning on UK legal proceedings related toour type 2 diabetes medicine Avandia (rosiglitazone), we would like to make the following points: We have every sympathy for people with health …
Issued: Tuesday 5 February 2013, London UK – LSE Announcement GlaxoSmithKline plc (LSE: GSK) announced today that, pursuant to the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte. Ltd, GSK has successfully increased its stake in …
Issued: Tuesday 5 February 2013, London UK GSK today further demonstrated its commitment to clinical trial transparency by announcing its support for the AllTrials campaign. The campaign is calling for registration of clinical trials and the disclosure of …
Issued Wednesday 6 February 2012 - LSE announcement GSK delivers 2012 core EPS of 112.7p and returns £6.3 billion to shareholders Group sales -1%; flat excluding disposals of OTC brands Successful RD delivery: 6 new drugs filed since start of 2012 Phase …
Issued: Thursday 7 February 2013, London UK – LSE Announcement GlaxoSmithKline (GSK) plc today announced submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for trametinib (MEK) as monotherapy and in combination with …
